TAIWAN BIO THERAPEUTICS INC.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppre
Founded Year
2014
Unified Business No.
24571303
Status
Active
Number of Employees
0
Total Paid-in
Capital
940,152,280 (NT$)
Location of Company
Taiwan
, Hsinchu County
Exit Status
Emerging Stock Exchange(2025)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Taiwan Bio is dedicated to driving innovation and expanding access to cell therapies. Through our FAST CGT platform, we reduce costs, enhance efficacy, accelerate development, and streamline production, setting new milestones in the treatment of chronic and immune-related diseases. Originating in Taiwan, our technology is now expanding globally through strategic collaborations with leading U.S. universities and research institutions, fostering a robust cell therapy ecosystem.
